A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA
Grant Award Details
Grant Type:
Grant Number:
CLIN2-14265
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$11,637,194
Status:
Active
Grant Application Details
Application Title:
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA
Public Abstract:
Therapeutic Candidate or Device
GNSC-001 is an adeno-associated vector (AAV) expressing an optimized form of IL-1Ra, a naturally occurring protein that blocks IL-1 signaling.
Indication
Osteoarthritis of the knee
Therapeutic Mechanism
GNSC-001 is an adeno-associated virus (AAV) gene therapy vector that expresses IL-1Ra and confers long-term IL-1 inhibition following a single, local injection into the affected joint. By blocking IL-1 signaling, GNSC-001 is expected to improve inflammation, symptoms (pain/function), and slow or reverse disease progression (cartilage degeneration) in osteoarthritis patients.
Unmet Medical Need
Osteoarthritis is a degenerative joint disease that is the leading cause of disability. Current treatments are only palliative; nothing can slow or stop osteoarthritis progression. GNSC-001 is injected into the knee, blocking IL-1 signaling to reduce inflammation, pain, and joint degeneration.
Project Objective
Phase 1b trial completed; ready for Phase 2b
Major Proposed Activities
GNSC-001 is an adeno-associated vector (AAV) expressing an optimized form of IL-1Ra, a naturally occurring protein that blocks IL-1 signaling.
Indication
Osteoarthritis of the knee
Therapeutic Mechanism
GNSC-001 is an adeno-associated virus (AAV) gene therapy vector that expresses IL-1Ra and confers long-term IL-1 inhibition following a single, local injection into the affected joint. By blocking IL-1 signaling, GNSC-001 is expected to improve inflammation, symptoms (pain/function), and slow or reverse disease progression (cartilage degeneration) in osteoarthritis patients.
Unmet Medical Need
Osteoarthritis is a degenerative joint disease that is the leading cause of disability. Current treatments are only palliative; nothing can slow or stop osteoarthritis progression. GNSC-001 is injected into the knee, blocking IL-1 signaling to reduce inflammation, pain, and joint degeneration.
Project Objective
Phase 1b trial completed; ready for Phase 2b
Major Proposed Activities
- Enroll 50 osteoarthritis patients in a Phase 1b trial; assess safety and pharmacodynamics of GNSC-001 at two dose levels.
- Evaluate the effect of GNSC-001 on symptoms and biomarkers of disease progression over time.
- Prepare for next phase of development by scaling up the GNSC-001 manufacturing process and meeting with FDA to discuss requirements for approval.
Statement of Benefit to California:
Arthritis affects over 5.9 million Californians (20%). Osteoarthritis is the leading cause of disability; current treatments are limited to pain management. GNSC-001 has the potential to alleviate osteoarthritis pain and function, and slow or reverse its progression, for millions of Californians suffering from this disease. In addition, this research supports Genascence as a California corporation, and includes clinical work in California, directly fostering innovation and creating local jobs.